Q BioMed Technology Partner Mannin Research Inc. Presents Data Showing Potential Treatment to Protect the Kidney in Acute Kidney Injury Using Mannin Tie2 Activator

Tuesday, November 26, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Data presented during "Acute Kidney Injury" symposium at the American Society for Nephrology 2019 Annual Meeting Expands Pipeline of Platform Technology

NEW YORK, Nov. 26, 2019 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, is announcing today that its technology research partner Mannin Research Inc. (Mannin) presented positive data on a potential new treatment for acute kidney injury (AKI). The data was presented at the American Society for Nephrology 2019 Annual Meeting held in Washington DC. 

In the US alone, the cost of hospitalizations for patients with complications arising from AKI can range between $5.4 and $24.0 billion1. There is a significant opportunity to advance a therapeutic solution to treat AK and address a patient population that contributes to 20% of all hospitalizations in the US2.  Current treatments for AKI are mainly supportive and do not treat the underlying condition3.

Mannin's Chief Scientific Officer, Dr. Susan Quaggin, presented data that showed that the Ang-Tie2 signaling pathway is a promising therapeutic target to prevent AKI after ischemia caused by ischemia–reperfusion (IR) injury to the kidney.  Ischemia in the kidney occurs in a range of clinically important scenarios such as hypotension, sepsis, and cardiovascular events such as strokes.

"We are very encouraged by this data. Taken together with our recently announced funding and establishment of a research center in Saxony, Germany, this data will enable us to advance our program in developing therapeutics to treat acute kidney injury, bolstering our pipeline," said Dr. Nikopoulos. "We look forward to the day when we can make a difference in the lives of patients with kidney and cardiovascular diseases."

Q BioMed and Mannin have been partners since 2015 and Q BioMed has an exclusive option on all Mannin portfolio assets.

About Q BioMed Inc.

Q BioMed Inc. is a biotech acceleration and commercial stage company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets; strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential, enabling them to provide products to patients in need?.

Please visit http://www.QBioMed.com and sign up for regular updates

About Mannin Research, Inc. 

Mannin Research Inc. is a biotechnology company focused on the discovery, development, and commercialization of therapeutics for vascular diseases using a novel mechanism of action. Mannin has a pipeline of novel therapeutics that can be developed from this research platform which would treat a spectrum of vascular diseases.

Forward-Looking Statements:

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.


  1. Levey, Andrew S., and Matthew T. James. "Acute Kidney Injury". Annals Of Internal Medicine, vol 167, no. 9, 2017, p. ITC66. American College Of Physicians, doi:10.7326/aitc201711070. Accessed 7 Nov 2019.
  2. Workeneh, Biruh T et al. "Acute Kidney Injury Treatment & Management: Approach Considerations, Vasodilators, Dietary Modification". Emedicine.Medscape.Com, 2019, https://emedicine.medscape.com/article/243492-treatment.
  3. Levey, Andrew S., and Matthew T. James. "Acute Kidney Injury". Annals Of Internal Medicine, vol 167, no. 9, 2017, p. ITC66. American College Of Physicians, doi:10.7326/aitc201711070. Accessed 7 Nov 2019.
Media Contact Mannin: George NikopoulosPresident and CEO+1-(416)-775-9767info@mannin.ca 

Media Contact Q BioMed: Denis CorinCEO+1(404) 995-6671ir@qbiomed.com

Cision View original content:http://www.prnewswire.com/news-releases/q-biomed-technology-partner-mannin-research-inc-presents-data-showing-potential-treatment-to-protect-the-kidney-in-acute-kidney-injury-using-mannin-tie2-activator-300964967.html

SOURCE Q BioMed Inc.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z



Premium Membership Benefits

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store